drugset / Trial / NCT00754715

Study to Assess Safety, Tolerability and Pharmacokinetics After Single Doses of AZD2516 to Healthy Volunteers

NCT00754715 ↗

Phase 1 Completed 72 enrolled AstraZeneca
RandomizedParallel-groupQuadruple-blindBasic science

Summary

The primary purpose of this study is to assess the safety and tolerability of AZD2516 following administration of a single dose.

Timeline

Start
2008-09
Primary completion
2008-11
Completion
2008-12

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD2516 Unknown — Oral

Indications

No indication recorded.